• OBJECTIVES
    • Giant cell tumor of bone (GCTB) is a locally aggressive tumor with a high recurrence rate. Using denosumab or its biosimilar in a neoadjuvant setting can facilitate limb-preserving surgery and reduce recurrence rates, with minimal side effects.
  • MATERIAL AND METHODS
    • In this clinical audit, we retrospectively analyzed the impact of denosumab biosimilar (DB) on Campanacci grade 3 GCTB, the most aggressive form of these tumors.
  • STATISTICAL ANALYSIS
    • Means and standard deviations were used for normally distributed continuous variables, medians and ranges for nonnormal continuous variables, and percentages for categorical variables.
  • RESULTS
    • All cases received two doses of DB on days 0 and 14, resulting in a mean lesion size reduction of 17.75%.
  • CONCLUSION
    • Our findings suggest that this treatment regimen can significantly improve outcomes for patients with aggressive GCTB, aiding orthopaedic oncologists in managing these challenging cases more effectively.